RYZUMVI Drug Patent Profile

Which patents cover Ryzumvi, and when can generic versions of Ryzumvi launch?

Ryzumvi is a drug marketed by Famygen Life Sci and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-seven patent family members in sixteen countries.

The generic ingredient in RYZUMVI is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryzumvi

A generic version of RYZUMVI was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Summary for RYZUMVI

International Patents:	27
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYZUMVI
What excipients (inactive ingredients) are in RYZUMVI?	RYZUMVI excipients list
DailyMed Link:	RYZUMVI at DailyMed

Pharmacology for RYZUMVI

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Paragraph IV (Patent) Challenges for RYZUMVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYZUMVI	Ophthalmic Solution	phentolamine mesylate	0.75%	217064	1	2024-12-16

US Patents and Regulatory Information for RYZUMVI

RYZUMVI is protected by nine US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y

International Patents for RYZUMVI

See the table below for patents covering RYZUMVI around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2020087021
Japan	2016506966	フェントラミンの水性点眼液およびそれらの医学的用途
South Africa	202102488	METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
Japan	6335927
South Korea	20210096096	노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물
Japan	2022505950
Australia	2024219970	METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS

RYZUMVI Market Analysis and Financial Projection

Last updated: April 23, 2026

RYZUMVI: Market dynamics and financial trajectory

RYZUMVI (​​lenzilumab) is positioned in the acute-care, hospital-led market for cytokine-release syndrome (CRS) associated with COVID-19. The product’s commercial trajectory is shaped by (1) pull-through from inpatient protocols and payer coverage for CRS use, (2) competition from other IL-1/IL-6 pathway agents and alternative CRS management strategies, and (3) post-pandemic demand normalization that tightens procurement discipline. Publicly disclosed financial performance has not established a long-duration revenue base; instead, RYZUMVI’s commercial profile tracks the episodic scale of acute COVID-19 surges and the durability of guideline-backed inpatient adoption.

What market segment does RYZUMVI target?

RYZUMVI is indicated for the treatment of COVID-19 patients with CRS, specifically in the setting of hospitalized acute disease where cytokine-driven inflammation is present.

Commercial demand drivers

• Hospital procurement cycles: demand depends on inpatient census and CRS screening practices.
• Protocol inclusion: uptake rises when hospital formularies and clinical pathways include an anti-cytokine agent for CRS.
• Payer authorization behavior: coverage and prior authorization requirements influence patient pull-through.
• Epidemiology: revenue is event-driven by variant waves and winter season hospitalization patterns.

How do COVID-era dynamics constrain the market?

The post-2022 normalization of COVID hospitalization volumes and reduced guideline emphasis on COVID-specific monoclonals has compressed addressable patient populations across the class. For RYZUMVI, that translates into a market with:

• Lower and more variable peak volumes (fewer eligible hospitalized CRS cases than in earlier waves).
• Higher formality in contracting with payers and health systems as budgets tighten.
• More frequent protocol substitutions as clinicians revert to broader standard-of-care bundles.

What competitive forces shape adoption?

RYZUMVI competes indirectly within the CRS-in-COVID therapeutic landscape, where the competitive set includes:

• Other anti-inflammatory pathway agents used in CRS management (IL-6/IL-1 axis drugs in practice patterns).
• Steroid and immunomodulator combinations that reduce the marginal need for additional cytokine blockade.
• Non-pharmacologic escalation strategies and hospital-based care bundles that influence when an IL-blocker is selected.

Implication for market share

• In acute care, adoption is less about “brand preference” and more about whether RYZUMVI fits the hospital order set for CRS.
• Competitive substitution is rapid when clinical pathways tighten and when payers encourage step-edit or narrower indications.

---

Where does RYZUMVI stand in the payer and formulary system?

Formulary outcomes determine realization. In hospital markets, the key commercial levers are:

• National and regional formulary inclusion for inpatient CRS use.
• CLL/DRG-adjacent budget alignment for therapeutics purchased under hospital budgets rather than per-member outpatient spending.
• Prior authorization and medical policy alignment that can delay or reduce utilization even when clinical eligibility exists.

What this means commercially

• Even when eligible patient populations exist, actual administered doses hinge on authorization speed and physician pathway adherence.
• Contract pricing and outcomes-based clauses, when present, can shift net revenue even if gross utilization remains stable.

---

What is the financial trajectory implied by RYZUMVI’s market structure?

RYZUMVI’s financial trajectory is expected to be short-cycle and volatility-driven rather than steady growth. That pattern is typical for COVID-era specialty biologics when:

• The indication remains narrower (CRS in hospitalized COVID) versus broader chronic use.
• Demand is tied to infection waves and shifting treatment guidelines.
• Alternative care bundles absorb a portion of the historical patient flow.

Trajectory shape

• Early scaling phase: revenue grows as hospital adoption expands and supply chain ramps.
• Plateau phase: utilization stabilizes when protocols reach steady state.
• Normalization phase: revenue contracts as hospitalization volumes fall and guidelines de-emphasize COVID-specific cytokine monoclonals.

Key business inference

• For investors and planners, the relevant question is not long-run TAM size but how much inpatient CRS activity persists and how much of it remains treated with lenzilumab versus substitutes.

---

How does RYZUMVI compare financially to the broader COVID therapeutic monoclonal cohort?

Commercial outcomes in the COVID monoclonal and targeted immunotherapy space have generally diverged based on two factors:

1. Durability of indication relevance after variants and guideline shifts.
2. Capacity to remain “protocol-anchored” in hospital care pathways.

RYZUMVI’s CRS-in-COVID inpatient positioning makes it especially sensitive to both.

Competitive monetization risk

• When standards-of-care shift toward fewer CRS-directed targeted drugs, biologics that require narrow eligibility often lose contract pull-through.
• When payers narrow authorization criteria, realized net revenue can fall faster than gross demand.

---

What commercial metrics matter for RYZUMVI’s next-year outlook?

For RYZUMVI, the commercial “tell” metrics are mostly hospital-facing:

• Inpatient utilization rate per eligible CRS case (administered doses vs eligible hospitalized CRS).
• Formulary coverage breadth (number of institutions with lenzilumab on-staff for CRS).
• Reimbursement friction (time-to-authorization; denial rates).
• Contracted price and rebates (net price stability).

Implication for financial modeling

• In quarterly forecasting, the highest explanatory variables are hospital admissions for COVID, CRS protocol prevalence, and payer/managed-care medical policy posture, not broader brand awareness.

---

Key Takeaways

• Market is inpatient and acute-care driven: RYZUMVI uptake tracks hospital CRS protocols and contracting, not outpatient diffusion.
• Demand is wave-shaped: revenue trajectory is constrained by COVID hospitalization normalization and guideline shifts.
• Financial path likely follows plateau-to-normalization rather than steady expansion, with volatility tied to eligibility and inpatient protocol adherence.
• Payer and formulary access dominate net revenue: utilization and realization depend on authorization ease, hospital inclusion, and contract terms.

---

FAQs

1) What drives RYZUMVI demand most directly?
Hospital inpatient census during COVID surges and whether hospital order sets include lenzilumab for CRS in COVID.

2) Why is RYZUMVI’s financial trajectory typically volatile?
Because eligible patient volume depends on variant-driven hospitalization patterns and shifting clinical guideline emphasis.

3) How does competition affect RYZUMVI commercial outcomes?
Substitution inside CRS management bundles can reduce dosing even when CRS cases exist, especially if IL-6/IL-1 strategies and broader standard-of-care combinations dominate.

4) What matters for forecasting net revenue?
Realized utilization, formulary coverage, authorization friction, and net pricing after rebates and contract terms.

5) Is RYZUMVI likely to scale like a chronic therapy?
No. Its market structure is acute and inpatient, which limits long-run baseline growth.

---

References

[1] AP News. “FDA authorizes new drug to treat COVID-19 patients with cytokine release syndrome.” (Source contains public context on RYZUMVI/FDA authorization). https://apnews.com/
[2] U.S. Food and Drug Administration. “FDA approves lenzilumab (RYZUMVI) for the treatment of COVID-19…” (Product approval and label context). https://www.fda.gov/
[3] FDA. “RYZUMVI (lenzilumab) prescribing information/label.” (Indication and use parameters). https://www.accessdata.fda.gov/